Teva Pharmaceutical Industries Outlines 2030 Revenue Targets for Innovative Medicines
Teva Pharmaceutical Industries (TEVA) has announced ambitious long-term financial targets ahead of its inaugural R&D Day event. The company aims to generate between $6 billion and $7 billion in annual revenue from its innovative medicines portfolio by the year 2030. These projections are a central component of Teva's 'Pivot to Growth' strategy, which was initiated in 2023 to shift the company's focus toward high-value specialty products. The roadmap highlights a strategic transition intended to drive sustainable growth through increased investment in research and development.
Tickers: $TEVA
Topics: innovative medicines R&D strategy revenue projections